Most of us know someone who has watched Alzheimer's disease slowly change a parent, a grandparent or a neighbor. The disease is still one of the hardest to treat. Every new drug comes with both hope and a long list of small print.
Researchers at Indiana University School of Medicine reported a new class of compounds that reduced the brain plaques tied to Alzheimer's in mice. The study was published October 14, 2026 in the journal Advanced Science.
The compound is a small molecule, meant to be given as a pill. The Alzheimer's disease-modifying drugs approved so far work differently. They are antibodies, delivered by infusion in a clinic.
That difference matters because of a known side effect of those infusions. On brain scans, some patients develop swelling or small bleeds in the brain, grouped under the name ARIA.
Also read: Is running bad for your knees? Here is what the evidence actually says
For the approved drug Leqembi, the published safety data list brain swelling in 13 percent of treated patients and small brain bleeds in 17 percent. About 3 percent had symptoms from it.
In the mouse study, the researchers reported no physical or behavioral abnormalities at the doses tested. That is not the same as safety in people. The compound has not yet been tested in a single human.
How the new approach works
Today's approved drugs mop up amyloid plaques after they have already formed. The Indiana University team is trying something earlier.
Their compound binds amyloid precursor protein, the raw material of the plaques, to a helper protein in the cell. The pair is then hauled off to the cell's recycling center and broken down.
Also read: 8 warning signs of perimenopause most women don't expect in their 40s
"Our approach seeks to intervene earlier by selectively reducing amyloid precursor proteins," said Chunhai Hao. He is Bicentennial Professor of Pathology and Laboratory Medicine II at Indiana University School of Medicine.
In the mouse experiments, the lead compound crossed the blood-brain barrier and lowered both the raw protein and the amyloid plaques in brain tissue.
Why early-stage research still matters here
Alzheimer's is a long disease that touches a lot of families. The Alzheimer's Association estimates that 7.4 million Americans aged 65 and older are living with it in 2026. Almost two-thirds are women.
Today's approved drugs slow decline modestly in some patients, and they come with real risks. A pill that works through a different pathway could, if it holds up, reach patients who cannot tolerate the infusions.
Also read: Berries, poultry and 2.5 extra years: What the MIND diet may do to your brain
A few caveats sit on top of the finding. Mouse studies often do not translate to humans. The team itself notes that more pharmacology and efficacy work has to come before any human trial.
The researchers have co-founded a company, Degrome Therapeutics, to try to move the compound into clinical testing.
Also read: Taking Ozempic or Wegovy? Researchers have flagged a rare but serious vision risk
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.